NASDAQ$IMRX
Immuneering Corporation · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Immuneering reported its first quarter 2025 financial results, highlighting progress in clinical trials and financial stability.
Immuneering reported a net loss of $15.0 million for Q1 2025, compared to $14.3 million in Q1 2024. The company's cash and cash equivalents stood at $35.9 million, with a cash runway extended into 2026. Clinical progress for IMM-1-104 in pancreatic cancer showed promising results, including a patient passing the 13-month mark on monotherapy.
- IMM-1-104 showed exceptional efficacy in pancreatic cancer patients, including a third-line monotherapy patient with over 13 months progression-free survival.
- The company announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® for non-small cell lung cancer.
- Dr. Igor Matushansky was appointed as Chief Medical Officer to lead clinical efforts, particularly for the planned Phase 3 trial in first-line pancreatic cancer.
- Immuneering extended its cash runway into 2026, providing financial stability for ongoing operations and clinical development.
Headline financials
Revenue & EPS history
Immuneering · Revenue · Quarterly
$0
Forward guidance
Immuneering expects initial progression-free survival data from the IMM-1-104 Phase 2a trial in Q2 2025 and plans to initiate a Phase 3 trial of IMM-1-104+mGnP in first-line pancreatic cancer in 2026. The company's cash runway is projected to fund operations into 2026.
Tailwinds
- Progression-free survival data from IMM-1-104 Phase 2a trial expected in 2Q'25.
- Planning for additional IMM-1-104 combination arms.
- Initiation of Phase 3 trial of IMM-1-104+mGnP in first-line pancreatic cancer planned for 2026.
- Cash runway extended into 2026.
- Continued positive clinical trial results for IMM-1-104.
Headwinds
- No specific negative forward guidance was provided in the report.
- Reliance on successful clinical trial outcomes for future progress.
- Potential for delays in clinical trials.
- Need for additional funding beyond 2026.
- Uncertainties inherent in oncology drug development.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2025
-4.3%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+3.7%
Avg return
30 days after
23%
5 / 22 earnings
Positive
+8.3%
Q4 2022
Best reaction
-13.0%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +6.8% | +13.5% | +9.4% | |
| Q3 2025 | -2.4% | +8.0% | -8.2% | |
| Q1 2025 | +4.9% | +0.7% | +64.6% | |
| Q4 2024 | -1.8% | +0.6% | -24.4% | |
| Q3 2024 | +6.0% | -1.6% | -10.7% | |
| Q2 2024 | -6.6% | -10.7% | -2.5% | |
| Q1 2024 | -1.2% | -12.1% | -14.5% | |
| Q4 2023 | -0.8% | +3.2% | -53.4% | |
| Q3 2023 | -12.1% | -10.8% | +24.9% | |
| Q2 2023 | -2.2% | -6.4% | -15.7% | |
| Q1 2023 | -9.3% | -11.2% | -0.6% | |
| Q4 2022 | +8.3% | +47.9% | +64.2% | |
| Q3 2022 | -12.5% | -16.3% | -40.1% | |
| Q2 2022 | -5.7% | -1.5% | +32.2% | |
| Q1 2022 | +3.0% | +17.2% | +49.9% | |
| Q4 2021 | -7.3% | -6.3% | +1.0% | |
| Q3 2021 | -5.4% | -10.2% | -29.5% | |
| Q3 2020 | -5.4% | -10.2% | -29.5% | |
| Q1 2021 | -13.0% | +8.5% | +16.2% | |
| Q2 2021 | -13.0% | +8.5% | +16.2% | |
| Q2 2020 | -13.0% | +8.5% | +16.2% | |
| Q4 2020 | -13.0% | +8.5% | +16.2% | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro